Original articleGeneral thoracicPersistent Lung Expansion After Pleural Talc Poudrage in Non-Surgically Resected Malignant Pleural Mesothelioma
Section snippets
Patients and Methods
Clinical and pathologic data of all patients referred to the Thoracic Surgery Unit of Novara (Italy) between January 2006 and December 2011 for video-assisted thoracoscopic (VAT) pleural biopsy and pleurodesis for pleural effusion were collected prospectively and analyzed retrospectively. The present study was approved by the Institutional Research Ethics Board and patient consent was deemed not necessary due to the retrospective nature of the study.
Patients with preoperative diagnosis of
Patient Characteristics
Among 172 patients affected by MPM submitted to VAT pleural biopsy and pleurodesis by talc poudrage 24 underwent surgery with a previous diagnosis of MPM, whereas the remaining (n = 148) had MPM diagnosis at the time of the procedure. Twenty-six patients did not have complete lung expansion at discharge, whereas the other 146 patients (84%) had demonstrated a complete lung expansion after chest drain removal. Table 1 shows the main demographic, clinical, and pathologic characteristics of the
Comment
In this study focusing on pleurodesis outcome in patients with MPM, all our patients received pleural talc insufflation during VAT. Pleurodesis success rate at follow-up was suboptimal. When only patients with complete lung expansion at discharge were considered, 58% patients had complete control of their MPM related effusion; if the entire population of patients submitted to VAT and pleurodesis was considered (172 patients), the success rate was lower (about 49%). The low success rate reported
References (30)
- et al.
MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Lancet Oncol
(2011) - et al.
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases
Chest
(1996) - et al.
Management of malignant mesothelioma
Clin Chest Med
(2006) - et al.
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group G
Chest
(1998) - et al.
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis
J Thorac Cardiovasc Surg
(2013) - et al.
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study
J Thorac Cardiovasc Surg
(2009) - et al.
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors
J Thorac Cardiovasc Surg
(2009) - et al.
Malignant pleural mesothelioma: surgical management in 285 patients
Ann Thorac Surg
(2008) - et al.
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center
J Thorac Oncol
(2007) - et al.
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure
Lung Cancer
(2012)
Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
Int J Cancer
Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005
Crit Rev Toxicol
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
Eur Respir J
Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases
Respiration
Pleurodesis outcome in malignant pleural mesothelioma
Thorax
Cited by (18)
Survival in patients with malignant pleural effusion undergoing talc pleurodesis
2019, Lung CancerCitation Excerpt :It could be argued that this survival difference is inherently related to the selection bias of better performance status patients who are offered pleurodesis; however, this difference was still observed when survival only in patients with higher performance status was studied [7]. Recent data suggest that a survival benefit is seen in MPE patients who have successful pleurodesis in comparison to those who fail pleurodesis and this has been reported in cohorts of patients with mesothelioma [8,9] and other malignancies [10] and where talc [9,11] or other substances such as bleomycin [10] were used to induce pleurodesis. This study aimed to explore whether there was a difference in survival according to pleurodesis outcome in patients with MPE undergoing pleurodesis using large databases of prospectively collected data on patients with MPE undergoing talc pleurodesis.
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience
2018, Journal of Thoracic and Cardiovascular SurgeryCitation Excerpt :Moreover, extended resections have a clear selection bias because only patients with an acceptable preoperative performance status are able to undergo these procedures. Lastly, in some reports no difference in terms of OS has been found between patients treated with multimodality treatment including EPP or EPD and those who received only systemic treatments.7,8,34 Our approach seems to fit all these criteria, and in our small cohort of patients, oncologic results seem to be at least comparable with those which were previously reported (Table 5).
Malignant Pleural Effusion: From Diagnostics to Therapeutics
2018, Clinics in Chest MedicineCitation Excerpt :Unfortunately, none of the MPE management strategies available to date have been shown to prolong survival, and the aim of management of patients with MPE is prevention of recurrence of pleural effusions and symptom control. A retrospective study including 172 patients with mesothelioma showed prolonged survival in patients who underwent successful talc pleurodesis at video-assisted thoracoscopy, compared with patients who had pleural fluid recurrence at 3 months; however, this finding needs to be confirmed in suitable randomized, prospective trials.47 Systemic chemotherapy, radiotherapy, or hormone therapy may control the MPE, especially in lymphoma, small cell lung cancer, and breast cancer.
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma
2017, European Journal of Surgical OncologyCitation Excerpt :We did not observe a statistically significant difference between overall survival of stage I and II, even though these statistical results might be related to the small number of our cohort. It has been suggested that surgery only have a marginal role on prognosis which might be influenced only by some innate feature of the cancer3,29; similarly Rena30 find out that patient undergoing palliative procedures to control pleural effusion and have a re expansion of the lung had a 2-year survival of 30%, very closed to those of patients who were aggressively treated with EPP. On the other hand, Rusch and coworker6 find a significant difference in survival between patients who received a palliative treatment and those who had a curative-intention treatment.
Progress in surgical treatment of malignant pleural mesothelioma
2023, Chinese Journal of Thoracic and Cardiovascular SurgeryTalc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis
2021, General Thoracic and Cardiovascular Surgery